Vaccine molecules targeting Xcr1 on cross‐presenting DCs induce protective CD8+ T‐cell responses against influenza virus

Targeting antigens to cross‐presenting dendritic cells (DCs) is a promising method for enhancing CD8⁺ T‐cell responses. However, expression patterns of surface receptors often vary between species, making it difficult to relate observations in mice to other animals. Recent studies have indicated that the chemokine receptor Xcr1 is selectively expressed on cross‐presenting murine CD8α⁺ DCs, and that the expression is conserved on homologous DC subsets in humans (CD141⁺ DCs), sheep (CD26⁺ DCs), and macaques (CADM1⁺ DCs). We therefore tested if targeting antigens to Xcr1 on cross‐presenting DCs using antigen fused to Xcl1, the only known ligand for Xcr1, could enhance immune responses. Bivalent Xcl1 fused to model antigens specifically bound CD8α⁺ DCs and increased proliferation of antigen‐specific T cells. DNA vaccines encoding dimeric Xcl1‐hemagglutinin (HA) fusion proteins induced cytotoxic CD8⁺ T‐cell responses, and mediated full protection against a lethal challenge with influenza A virus. In addition to enhanced CD8⁺ T‐cell responses, targeting of antigen to Xcr1 induced CD4⁺ Th1 responses and highly selective production of IgG2a antibodies. In conclusion, targeting of dimeric fusion vaccine molecules to CD8α⁺ DCs using Xcl1 represents a novel and promising method for induction of protective CD8⁺ T‐cell responses.     

Dendritic cells process synthetic long peptides better than whole protein,improving antigen presentation and T‐cell activation

The efficiency of antigen (Ag) processing by dendritic cells (DCs) is vital for the strength of the ensuing T‐cell responses. Previously, we and others have shown that in comparison to protein vaccines, vaccination with synthetic long peptides (SLPs) has shown more promising (pre‐)clinical results. Here, we studied the unknown mechanisms underlying the observed vaccine efficacy of SLPs. We report an in vitro processing analysis of SLPs for MHC class I and class II presentation by murine DCs and human monocyte‐derived DCs. Compared to protein, SLPs were rapidly and much more efficiently processed by DCs, resulting in an increased presentation to CD4⁺ and CD8⁺ T cells. The mechanism of access to MHC class I loading appeared to differ between the two forms of Ag. Whereas whole soluble protein Ag ended up largely in endolysosomes, SLPs were detected very rapidly outside the endolysosomes after internalization by DCs, followed by proteasome‐ and transporter associated with Ag processing‐dependent MHC class I presentation. Compared to the slower processing route taken by whole protein Ags, our results indicate that the efficient internalization of SLPs, accomplished by DCs but not by B or T cells and characterized by a different and faster intracellular routing, leads to enhanced CD8⁺ T‐cell activation.     

Dendritic cells expand antigen-specific Foxp3+CD25+CD4+ regulatory T cells including suppressors of alloreactivity

Summary: Thymic derived naturally occurring CD25⁺CD4⁺ T regulatory cells (Tregs) suppress immune responses, including transplantation. Here we discuss the capacity of dendritic cells (DCs) to expand antigen‐specific Tregs, particularly polyclonal Tregs directed to alloantigens. Initial studies have shown that mature DCs are specialized antigen‐presenting cells (APCs) for expanding antigen‐specific CD25⁺ CD4⁺ Tregs from TCR transgenic mice. When triggered by specific antigen, these Tregs act back on immature DCs to block the upregulation of CD80 and CD86 costimulatory molecules. More recently, DCs have been used to expand alloantigen‐specific CD25⁺CD4⁺ Tregs from the polyclonal repertoire in the presence of interleukin‐2 (IL‐2). Allogeneic DCs are much more effective than allogeneic spleen cells for expanding CD25⁺CD4⁺ Tregs. The DC‐expanded Tregs continue to express high levels of Foxp3, even without supplemental IL‐2, whereas spleen cells poorly sustain Foxp3 expression. When suppressive activity is tested, relatively small numbers of DC‐expanded CD25⁺CD4⁺ Tregs exert antigen‐specific suppression in the mixed leukocyte reaction (MLR), blocking immune responses to the original stimulating strain 10 times more effectively than to third party stimulating cells. DC‐expanded Tregs also retard graft versus host disease (GVHD) across full major histocompatibility complex (MHC) barriers. In vitro and in vivo, the alloantigen‐specific CD25⁺CD4⁺ Tregs are much more effective suppressors of transplantation reactions than polyclonal populations. We suggest that the expansion of Tregs from a polyclonal repertoire via antigen‐presenting DCs will provide a means for antigen‐specific control of unwanted immune reactions.     

Antigen processing and CD24 expression determine antigen presentation by splenic CD4+ and CD8+ dendritic cells

To examine heterogeneity in dendritic cell (DC) antigen presentation function, murine splenic DCs were separated into CD4⁺ and CD8⁺ populations and assessed for the ability to process and present particulate antigen to CD4⁺ and CD8⁺ T cells. CD4⁺ and CD8⁺ DCs both processed exogenous particulate antigen, but CD8⁺ DCs were much more efficient than CD4⁺ DCs for both major histocompatibility complex (MHC) class II antigen presentation and MHC class I cross-presentation. While antigen processing efficiency contributed to the superior antigen presentation function of CD8⁺ DCs, our studies also revealed an important contribution of CD24. CD8⁺ DCs were also more efficient than CD4⁺ DCs in inducing naïve T cells to acquire certain effector T-cell functions, for example generation of cytotoxic CD8⁺ T cells and interferon (IFN)-γ-producing CD4⁺ T cells. In summary, CD8⁺ DCs are particularly potent antigen-presenting cells that express critical costimulators and efficiently process exogenous antigen for presentation by both MHC class I and II molecules.     

CD4+ T‐cell activation is differentially modulated by bacteria‐primed dendritic cells,but is generally down‐regulated by n‐3 polyunsaturated fatty acids

Appropriate activation of CD4⁺ T cells is fundamental for efficient initiation and progression of acquired immune responses. Here, we showed that CD4⁺ T‐cell activation is dependent on changes in membrane n‐3 polyunsaturated fatty acids (PUFAs) and is dynamically regulated by the type of signals provided by dendritic cells (DCs). Upon interaction with DCs primed by different concentrations and species of gut bacteria, CD4⁺ T cells were activated according to the type of DC stimulus. The levels of CD80 were found to correlate to the levels of expression of CD28 and to the proliferation of CD4⁺ T cells, while the presence of CD40 and CD86 on DCs inversely affected inducible costimulator (ICOS) and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) levels in CD4⁺ T cells. For all DC stimuli, cells high in n‐3 PUFAs showed reduced ability to respond to CD28 stimulation, to proliferate, and to express ICOS and CTLA‐4. Diminished T‐cell receptor (TCR) and CD28 signalling was found to be responsible for n‐3 PUFA effects. Thus, the dietary fatty acid composition influences the overall level of CD4⁺ T‐cell activation induced by DCs, while the priming effect of the DC stimuli modulates CD80, CD86 and CD40 levels, thereby affecting and shaping activation of acquired immunity by differential regulation of proliferation and costimulatory molecule expression in CD4⁺ T cells.     

Unique functions of splenic CD8alpha+ dendritic cells during infection with intracellular pathogens

Deciphering the prerequisites for the induction of protective cytotoxic T cell responses is essential for future development of more effective CD8⁺ T cell-based vaccines against infectious diseases and cancer. Since crucial events for CD8⁺ T cell priming and differentiation occur during the first contacts of naïve T cells with distinct antigen-presenting cells (APCs), the identification and therapeutic targeting of these ‘master’ APCs has become a major quest in the field.A decade ago, dendritic cells (DCs) were discovered as potent APCs, as they combine all major features for the initiation of T cell responses: (1) naïve DCs demonstrate high endocytic activity and scan continuously their environment in strategic positions throughout the whole body; (2) after activation (e.g. during pathogen invasion), DCs migrate into T cell zones of their draining lymphatic compartments, meanwhile processing captured antigen and maturing in order to stimulate encountered antigen-specific T cells.During the last years, different subsets of DCs that can be distinguished by specific surface marker expression and effector functions have been identified in mice. Their distinct functional capabilities have led to the concept of work-sharing; “migrating” DCs primarily transport antigens to the lymph node, where a specialized subset of “resident” DCs, defined by the expression of the CD8αα homodimer (CD8α⁺ DCs), primes CD8⁺ T cells upon antigen cross-presentation. Accordingly, CD8α⁺ DCs have been found to prime CD8⁺ T cells against different viruses as well as intracellular bacteria such as Listeria monocytogenes (L.m.).Recently, L.m. was found to survive specifically in splenic CD8α⁺ DCs shortly after intravenous infection. Further experiments revealed a more generalized sampling activity of CD8α⁺ DCs for blood-borne particles. These findings indicate that splenic CD8α⁺ DCs might unite efficacious antigen-trapping with the licence to prime CD8⁺ T cells. This new aspect of DC function could have evolved to guarantee a more rapid antigen-specific response against generalized infections.     

Sustained cross‐presentation capacity of murine splenic dendritic cell subsets in vivo

An exclusive feature of dendritic cells (DCs) is their ability to cross‐present exogenous antigens in MHC class I molecules. We analyzed the fate of protein antigen in antigen presenting cell (APC) subsets after uptake of naturally formed antigen‐antibody complexes in vivo. We observed that murine splenic DC subsets were able to present antigen in vivo for at least a week. After ex vivo isolation of four APC subsets, the presence of antigen in the storage compartments was visualized by confocal microscopy. Although all APC subsets stored antigen for many days, their ability and kinetics in antigen presentation was remarkably different. CD8α⁺ DCs showed sustained MHC class I‐peptide specific CD8⁺ T‐cell activation for more than 4 days. CD8α^? DCs also presented antigenic peptides in MHC class I but presentation decreased after 48 h. In contrast, only the CD8α^? DCs were able to present antigen in MHC class II to specific CD4⁺ T cells. Plasmacytoid DCs and macrophages were unable to activate any of the two T‐cell types despite detectable antigen uptake. These results indicate that naturally occurring DC subsets have functional antigen storage capacity for prolonged T‐cell activation and have distinct roles in antigen presentation to specific T cells in vivo.     

Species‐dependent role of type I IFNs and IL‐12 in the CTL response induced by humanized CpG complexed with β‐glucan

CpG oligodeoxynucleotide (ODN) is one of promising nucleic acid‐based adjuvants. We recently improved its ability to enhance CD8⁺ T‐cell responses to coadministered protein antigen without conjugation or emulsion, by forming a nanoparticulate complex between CpG ODN (K3) and mushroom‐derived β‐glucan schizophyllan (SPG), namely K3‐SPG. Here, we sought to elucidate the cellular immunological mechanisms by which K3‐SPG induce such potent CD8⁺ T‐cell responses to coadministered antigen. By focusing on two DC subsets, plasmacytoid DCs and CD8α⁺ DCs, as well as the secreted cytokines, IFN‐α and IL‐12, we found that K3‐SPG strongly activates mouse plasmacytoid DCs to secrete IFN‐α and CD8α⁺ DCs to secrete IL‐12, respectively. Although a single cytokine deficiency had no impact on adjuvant effects, the lack of both type I IFN and IL‐12 in mice resulted in a significant reduction of Th1 type immune responses and CD8⁺ T‐cell responses elicited by protein vaccine model. By sharp contrast, type I IFN, but not IL‐12, was required for the production of IFN‐γ by human PBMCs as well as antigen‐specific CD8⁺ T‐cell proliferation. Taken together, K3‐SPG may overcome the species barrier for CpG ODN to enhance antigen‐specific CD8⁺ T‐cell responses despite the differential role of IL‐12 between human and mice.     

Dendritic cells activated by an anti‐inflammatory agent induce CD4+ T helper type 2 responses without impairing CD8+ memory and effector cytotoxic T‐lymphocyte responses

Prevalence of pro‐inflammatory diseases is rising in developed country populations. The increase in these diseases has fuelled the search for new, immune suppressive, anti‐inflammatory therapies, which do not impact, or minimally impact, CD4⁺ and/or CD8⁺ T‐cell‐mediated immunity. The goal of this study was to determine if antigen‐presenting cells (APCs) activated by the anti‐inflammatory oligosaccharide, lacto‐N‐fucopentaose III (LNFPIII), would have an impaired ability to drive CD4⁺ T helper (Th) or CD8⁺ memory and effector T‐cell responses. To investigate this we activated splenic dendritic cells (SDCs) with LNFPIII and examined their ability to drive antigen‐specific CD4⁺ Th, and CD8⁺ memory and cytotoxic T‐cell (CTL) responses compared with lipopolysaccharide (LPS) ‐stimulated SDCs. The LNFPIII‐activated SDCs had altered co‐stimulatory molecule expression compared with LPS‐stimulated SDCs, while the levels of SDC chemokines following activation by either compound were similar. LNFPIII‐activated SDCs produced significantly lower levels of interleukin‐12 but surprisingly higher levels of interleukin‐6 than LPS‐activated SDCs. Similar to previous studies using bone‐marrow‐derived DCs, LNFPIII‐activated SDCs induced strong Th2 responses in vivo and ex vivo. LNFPIII activation of APCs was independent of the Toll‐interleukin‐1 receptor adaptor myeloid differentiating factor 88. Importantly, LNFPIII‐matured DCs induced CD8⁺ memory and effector CTL responses similar to those driven by LPS‐matured DCs, including the frequency of interferon‐γ‐producing CD8⁺ T cells and induction of CTL effectors. Treatment of APCs by the anti‐inflammatory glycan LNFPIII did not impair their ability to drive CD8⁺ effector and memory cell‐mediated immunity.     

Subcutaneous cholera toxin exposure induces potent CD103+ dermal dendritic cell activation and migration

CD103⁺ dermal dendritic cells (dDCs) are a recently described DC subset of the skin shown to be the principal migratory DCs capable of efficiently cross‐presenting antigens and activating CD8⁺ T cells. Harnessing their activity would promote vaccine efficacy, but it has been unclear how this can be achieved. We tested a panel of adjuvants for their ability to affect dDCs. In comparison to the other adjuvants tested, the capacity of cholera toxin (CT) to induce the migration of dDCs was unique. Within 24 h of CT injection, large numbers of highly activated dDCs (including CD103⁺ dDCs) migrated to the draining lymph nodes and cross‐presented coinjected antigens, potently activating naïve CD8⁺ T cells. Peptide vaccines adjuvanted with CT induced T‐cell responses uniquely characterized by dynamic cytokine responses including the production of IL‐2, and such vaccines were protective in situations reliant on CD8⁺ T‐cell responses, including liver‐stage Plasmodium challenge, or tumor challenge. This study is the first to examine the effects of adjuvants on CD103⁺ dDCs and identifies CT as a prototypical adjuvant for the activation of CD103⁺ dDCs, opening the way to development of vaccines and adjuvants that specifically target dDCs and generate effective CD8⁺ T‐cell responses.     

A CD40/CD40L feedback loop drives the breakdown of CD8+ T‐cell tolerance following depletion of suppressive CD4+ T cells

Dendritic cells (DCs) are the key APCs not only for the priming of naïve T cells, but also for the induction and maintenance of peripheral T‐cell tolerance. We have recently shown that cognate interactions between Foxp3⁺ Tregs and steady‐state DCs are crucial to maintain the tolerogenic potential of DCs. Using DIETER mice, which allow the induction of antigen presentation selectively on DCs without altering their maturation status, we show here that breakdown of CD8⁺ T‐cell tolerance, which ensues after depletion of suppressive CD4⁺ T cells, is driven by a positive feedback loop in which autoreactive CD8⁺ T cells activate DCs via CD40. These data identify ligation of CD40 on DCs as a stimulus that promotes autoreactive T‐cell priming when regulatory T‐cell suppression fails and suggest that feedback from autoreactive T cells to DCs may contribute to the well‐documented involvement of CD40 in many autoimmune diseases.     

New insights into the role of the aryl hydrocarbon receptor in the function of CD11c+ cells during respiratory viral infection

The aryl hydrocarbon receptor (AHR) has garnered considerable attention as a modulator of CD4⁺ cell lineage development and function. It also regulates antiviral CD8⁺ T‐cell responses, but via indirect mechanisms that have yet to be determined. Here, we show that during acute influenza virus infection, AHR activation skews dendritic‐cell (DC) subsets in the lung‐draining lymph nodes, such that there are fewer conventional CD103⁺ DCs and CD11b⁺ DCs. Sorting DC subsets reveals AHR activation reduces immunostimulatory function of CD103⁺ DCs in the mediastinal lymph nodes, and decreases their frequency in the lung. DNA‐binding domain Ahr mutants demonstrate that alterations in DC subsets require the ligand‐activated AHR to contain its inherent DNA‐binding domain. To evaluate the intrinsic role of AHR in DCs, conditional knockouts were created using Cre‐LoxP technology, which revealed that AHR in CD11c⁺ cells plays a key role in controlling the acquisition of effector CD8⁺ T cells in the infected lung. However, AHR within other leukocyte lineages contributes to diminished naïve CD8⁺ T‐cell activation in the draining lymphoid nodes. These findings indicate DCs are among the direct targets of AHR ligands in vivo, and AHR signaling modifies host responses to a common respiratory pathogen by affecting the complex interplay of multiple cell types.     

Thymic but not splenic CD8⁺ DCs can efficiently cross-prime T cells in the absence of licensing factors

Cross‐presentation is an important mechanism to elicit both immune defenses and tolerance. Although only a few DC subsets possess the machinery required for cross‐presentation, little is known about differences in cross‐presenting capabilities of DCs belonging to the same subpopulation but localized in different lymphoid organs. In this study, we demonstrate that steady‐state thymic CD8⁺ DCs can efficiently cross‐prime naïve CD8⁺ T cells in the absence of costimulation. Surprisingly, cross‐priming by splenic CD8⁺ DCs was dependent on licensing factors such as GM‐CSF. In the absence of GM‐CSF, antigen–MHC‐class‐I complexes were detected on thymic but not on splenic CD8⁺ DCs, indicating that the cross‐presentation capacity of the thymic subpopulation was higher. The observed cross‐priming differences between thymic and splenic CD8⁺ DCs did not correlate with differential antigen capture or costimulatory molecules found on the surface of DCs. Moreover, we did not detect overall impairment of antigen presentation, as peptide‐loaded splenic CD8⁺ DCs were able to induce CD8⁺ T‐cell proliferation. The observation that thymic CD8⁺ DCs are more efficient than splenic CD8⁺ DCs in T‐cell cross‐priming in the absence of licensing factors indicates that the requirements for efficient antigen presentation differ between these cells.     

DX5+CD4+ T cells modulate CD4+ T‐cell response via inhibition of IL‐12 production by DCs

DX5⁺CD4⁺ T cells have been shown to dampen collagen‐induced arthritis and delayed‐type hypersensitivity reactions in mice. These cells are also potent modulators of T‐helper cell responses through direct effects on CD4⁺ T cells in an IL‐4 dependent manner. To further characterize this T‐cell population, we studied their effect on DCs and the potential consequences on T‐cell activation. Here, we show that mouse DX5⁺CD4⁺ T cells modulate DCs by robustly inhibiting IL‐12 production. This modulation is IL‐10 dependent and does not require cell contact. Furthermore, DX5⁺CD4⁺ T cells modulate the surface phenotype of LPS‐matured DCs. DCs modulated by DX5⁺CD4⁺ T‐cell supernatant express high levels of the co‐inhibitor molecules PDL‐1 and PDL‐2. OVA‐specific CD4⁺ T cells primed with DCs exposed to DX5⁺CD4⁺ T‐cell supernatant produce less IFN‐γ than CD4⁺ T cells primed by DCs exposed to either medium or DX5^?CD4⁺ T‐cell supernatant. The addition of IL‐12 to the co‐culture with DX5⁺ DCs restores IFN‐γ production. When IL‐10 present in the DX5⁺CD4⁺ T‐cell supernatant is blocked, DCs re‐establish their ability to produce IL‐12 and to efficiently prime CD4⁺ T cells. These data show that DX5⁺CD4⁺ T cells can indirectly affect the outcome of the T‐cell response by inducing DCs that have poor Th1 stimulatory function.     

Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma

Background Dendritic cells (DCs) are antigen‐presenting cells that efficiently activate T cells. Objective We examined the effects of suplatast tosilate, which prevents T‐helper type 2 responses, on the differentiation and function of monocyte‐derived DCs (moDCs). Methods DCs were differentiated in vitro from peripheral monocytes from patients with asthma by the addition of granulocyte macrophage colony‐stimulating factor and IL‐4 in the presence or absence of suplatast tosilate. Cell surface molecules (CD1a, CD14, CD80, CD83, CD86, HLA‐DR) on immature and mature DCs were analysed with flow cytometry, and the secretion of CC chemokine ligand (CCL)17 (thymus and activation‐regulated chemokine), IL‐12p70, IL‐12p40, and IL‐10 was measured with an ELISA. We also studied the proliferative responses of allogeneic CD4⁺ T cells from healthy subjects to DCs differentiated in the presence of suplatast tosilate. In addition, the production of IFN‐γ and IL‐5 by CD4⁺ T cells after coculture with untreated DCs or suplatast tosilate‐treated DCs was measured with ELISA. Results Suplatast tosilate significantly inhibited the expression of CD1a, CD80, and CD86 on immature DCs and of CD1a, CD80, CD83, and CD86 on mature DCs. Suplatast tosilate also significantly inhibited the secretion of CCL17, IL‐12p70, and IL‐12p40; however, the secretion of IL‐10 was not affected. The proliferative responses of allogeneic CD4⁺ T cells to suplatast tosilate‐treated DCs were suppressed. Moreover, suplatast tosilate‐treated DCs had an impaired capacity to stimulate CD4⁺ T cells to produce IFN‐γ and IL‐5. Conclusion Suplatast tosilate inhibits the differentiation, maturation, and function of moDCs.     

In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens

T lymphocyte responses to hepatitis B virus (HBV) core antigen (HBcAg) are vigorous and easily detectable in vitro during recovery from acute hepatitis B but significantly weaker in patients with chronic HBV infection. In contrast, T cell responses to hepatitis B surface antigen (HBsAg) are almost undetectable during infection and even in a substantial fraction of subjects receiving vaccination with HBsAg. The aim of this study was to investigate whether the use of dendritic cells (DCs) in an in vitro assay could increase the detection of HBV‐specific T cells in these conditions. Autologous monocyte‐derived DCs, compared to direct HBsAg addition to the cultures, increased the stimulation of HBs‐ specific T cells. These were detected in 73% of healthy subjects who had recently received hepatitis B vaccine and in 43% of patients recovering from acute hepatitis B. Likewise, proliferation in response to DC‐presented HBcAg was detected in both CD4⁺ and CD8⁺ T cells from the majority of chronic hepatitis B patients. A longitudinal evaluation of HBc‐specific T cell responses during and after a 1‐year treatment with pegylated interferon (IFN)‐α showed that HBc‐specific CD4⁺ T cell responses had no correlation with sustained virus suppression whereas CD8⁺ T cell responses were more frequently detected in patients able to control HBV replication after therapy interruption. The use of autologous DCs as antigen‐presenting cells appears applicable to clinically relevant in vitro evaluation of T cell responses, particularly in those conditions characterized by low frequency of circulating antigen‐specific cells and suboptimal in vivo activation. J. Med. Virol. 81:332–339, 2009. © 2008 Wiley‐Liss, Inc.     

DNGR‐1 is dispensable for CD8+ T‐cell priming during respiratory syncytial virus infection

During respiratory syncytial virus (RSV) infection CD8⁺ T cells both assist in viral clearance and contribute to immunopathology. CD8⁺ T cells recognize viral peptides presented by dendritic cells (DCs), which can directly present viral antigens when infected or, alternatively, “cross‐present” antigens after endocytosis of dead or dying infected cells. Mouse CD8α⁺ and CD103⁺ DCs excel at cross‐presentation, in part because they express the receptor DNGR‐1 that detects dead cells by binding to exposed F‐actin and routes internalized cell debris into the cross‐presentation pathway. As RSV causes death in infected epithelial cells, we tested whether cross‐presentation via DNGR‐1 is necessary for CD8⁺ T‐cell responses to the virus. DNGR‐1‐deficient or wild‐type mice were intranasally inoculated with RSV and the magnitude of RSV‐specific CD8⁺ T‐cell induction was measured. We found that during live RSV infection, cross‐presentation via DNGR‐1 did not have a major role in the generation of RSV–specific CD8⁺ T‐cell responses. However, after intranasal immunization with dead cells infected with RSV, a dependence on DNGR‐1 for RSV‐specific CD8⁺ T‐cell responses was observed, confirming the ascribed role of the receptor. Thus, direct presentation by DCs may be the major pathway initiating CD8⁺ T‐cell responses to RSV, while DNGR‐1‐dependent cross‐presentation has no detectable role.     

Cover Picture: Eur. J. Immunol. 8'14

This month's cover features an immunofluorescent image of a dendritic cell (DC) loaded with apoptotic T‐cell blasts, in which HLA‐DR is stained blue and the early endosomal marker EEA‐1 is highlighted. The image is taken from the article by Valente et al. (pp. 2274–2286) in which the authors examine the T‐cell responses elicited by DCs that capture self antigen via engulfment of apoptotic cells. The authors found that CD4⁺ T cells stimulated with apoptotic cell‐loaded DCs are suppressive, but in the presence of bacterial lipopolysaccharide, these DCs generate IL‐17‐producing T cells. These findings highlight that DCs capturing apoptotic material induce unexpectedly robust autologous T‐cell responses.     

Compartmentalization of dendritic cell and T‐cell interactions in the lymph node: Anatomy of T‐cell fate decisions

Upon receiving cognate and co‐stimulatory priming signals from antigen (Ag)‐presenting dendritic cells (DCs) in secondary lymphoid tissues, naïve CD4⁺ T cells differentiate into distinct effector and memory populations. These alternate cell fate decisions, which ultimately control the T‐cell functional attributes, are dictated by programming signals provided by Ag‐bearing DCs and by other cells that are present in the microenvironment in which T‐cell priming occurs. We know that DCs can be subdivided into multiple populations and that the various DC subsets exhibit differential capacities to initiate development of the different CD4⁺ T‐helper populations. What is less well understood is why different subanatomic regions of secondary lymphoid tissues are colonized by distinct populations of Ag‐presenting DCs and how the location of these DCs influences the type of T‐cell response that will be generated. Here we review how chemokine receptors and their ligands, which position allergen and nematode‐activated DCs within different microdomains of secondary lymphoid tissues, contribute to the establishment of IL‐4 committed follicular helper T and type 2 helper cell responses.